117 related articles for article (PubMed ID: 12747280)
21. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.
Oleesky DA; Daniels RH; Williams BD; Amos N; Morgan BP
Clin Exp Immunol; 1991 May; 84(2):250-5. PubMed ID: 2025952
[TBL] [Abstract][Full Text] [Related]
22. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis.
Lehto T; Honkanen E; Teppo AM; Meri S
Kidney Int; 1995 May; 47(5):1403-11. PubMed ID: 7543624
[TBL] [Abstract][Full Text] [Related]
23. Increased susceptibility to erythrocyte C5b-9 deposition and complement-mediated lysis in chronic renal failure.
Himmelfarb J; McMonagle E; Holbrook D; Hakim R
Kidney Int; 1999 Feb; 55(2):659-66. PubMed ID: 9987090
[TBL] [Abstract][Full Text] [Related]
24. Pathological study on the relationship between C4d, CD59 and C5b-9 in acute renal allograft rejection.
Nishi S; Imai N; Ito Y; Ueno M; Fukase S; Mori H; Arakawa M; Bassam A; Saito K; Takahashi K; Gejyo F
Clin Transplant; 2004; 18 Suppl 11():18-23. PubMed ID: 15191368
[TBL] [Abstract][Full Text] [Related]
25. Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.
Ohi H; Tamano M; Sudo S; Okada N
Am J Kidney Dis; 2003 Jan; 41(1):179-85. PubMed ID: 12500235
[TBL] [Abstract][Full Text] [Related]
26. Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.
Goswami MT; Reka AK; Kurapati H; Kaza V; Chen J; Standiford TJ; Keshamouni VG
Oncogene; 2016 Apr; 35(15):1888-98. PubMed ID: 26148233
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
28. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
Chen S; Caragine T; Cheung NK; Tomlinson S
Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
[TBL] [Abstract][Full Text] [Related]
29. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.
Hamilton KK; Ji Z; Rollins S; Stewart BH; Sims PJ
Blood; 1990 Dec; 76(12):2572-7. PubMed ID: 1702330
[TBL] [Abstract][Full Text] [Related]
30. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
[TBL] [Abstract][Full Text] [Related]
31. Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.
Marchbank KJ; Morgan BP; van den Berg CW
Immunology; 1995 May; 85(1):146-52. PubMed ID: 7543447
[TBL] [Abstract][Full Text] [Related]
32. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors.
Ballanti E; Perricone C; di Muzio G; Kroegler B; Chimenti MS; Graceffa D; Perricone R
Autoimmun Rev; 2011 Aug; 10(10):617-23. PubMed ID: 21549221
[TBL] [Abstract][Full Text] [Related]
33. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.
Babiker AA; Nilsson B; Ronquist G; Carlsson L; Ekdahl KN
Prostate; 2005 Feb; 62(2):105-14. PubMed ID: 15389819
[TBL] [Abstract][Full Text] [Related]
34. Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction.
Väkevä A; Lehto T; Takala A; Meri S
Scand J Immunol; 2000 Oct; 52(4):411-4. PubMed ID: 11013013
[TBL] [Abstract][Full Text] [Related]
35. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
36. Recombinant soluble CD59 inhibits reactive haemolysis with complement.
Sugita Y; Ito K; Shiozuka K; Suzuki H; Gushima H; Tomita M; Masuho Y
Immunology; 1994 May; 82(1):34-41. PubMed ID: 7519172
[TBL] [Abstract][Full Text] [Related]
37. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.
Davies CS; Harris CL; Morgan BP
Immunology; 2005 Feb; 114(2):280-6. PubMed ID: 15667573
[TBL] [Abstract][Full Text] [Related]
38. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.
Halstead SK; O'Hanlon GM; Humphreys PD; Morrison DB; Morgan BP; Todd AJ; Plomp JJ; Willison HJ
Brain; 2004 Sep; 127(Pt 9):2109-23. PubMed ID: 15289269
[TBL] [Abstract][Full Text] [Related]
39. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia.
Barros MM; Yamamoto M; Figueiredo MS; Cançado R; Kimura EY; Langhi DM; Chiattone CS; Bordin JO
Transfusion; 2009 Jan; 49(1):154-60. PubMed ID: 18954403
[TBL] [Abstract][Full Text] [Related]
40. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis.
Rooney IA; Atkinson JP; Krul ES; Schonfeld G; Polakoski K; Saffitz JE; Morgan BP
J Exp Med; 1993 May; 177(5):1409-20. PubMed ID: 7683035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
